Regulatory ProfessionalsRegulatory ProfessionalsRegulatory ProfessionalsRegulatory Professionals
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Regulatory Affairs Strategy
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Quality Assurance
    • Project Management
    • Electronic Trial Master File | eTMF
  • Resources
    • Blog
    • White Papers
    • News
  • Careers
  • Contact

COVID-19 & Clinical Trials: Direct-to-Patient Model Keeps Research Moving and Patients Safe

    Home Blog COVID-19 & Clinical Trials: Direct-to-Patient Model Keeps Research Moving and Patients Safe
    NextPrevious

    COVID-19 & Clinical Trials: Direct-to-Patient Model Keeps Research Moving and Patients Safe

    By Andrea Ochoa | Blog, COVID-19 | Comments are Closed | 7 April, 2020 | 0

    In an effort to maintain the continuity of our clinical trials during the COVID-19 pandemic, Premier Research is helping customers take steps to safeguard the well-being of patients who were previously expected to go to a medical facility to receive treatment.

    A Direct-to-Patient (DTP) model applies only to studies for which the sponsor has had site closures as a result of COVID-19 and has requested direct shipping from the site to a patient’s home. Various factors have to be taken into consideration in the risk assessments, such as the ability of the patients to receive and self-administer the drug, the shipping conditions required, or whether the presence of a home nurse is necessary to facilitate administration. By following this process, we have identified those clinical studies that can be done virtually and for which the study drug can be shipped directly to patients.

    Because of the time sensitivity and concern for patient safety, this measure does not require prior approval by an Ethics Committee (EC) or Institutional Review Board (IRB). However, it does call for an understanding of each country’s requirements to know when submissions such as urgent safety measures, amendments, or notifications are still required.

    Critical to our process is ensuring that patient privacy remains protected. This is accomplished through using approved contracted courier services that collect the clinical trial material (CTM) and investigational medicinal product (IMP) from the investigator site or pharmacy and delivers it directly to the patient’s home or to a named responsible person, such as a home care nurse or relative. Patient privacy restricts the courier from having access to any health information; only the patient’s name and home address is supplied to them so that the courier can deliver the CTM/IMP. Likewise, where a home nursing visit is also required, only approved vendors will be performing the visits.

    When DTP services are to be used, site personnel must inform patients about the updated delivery method due to the emergency situation and the changes to how their personal information will be shared and processed. A follow-up letter should then be sent to patients so that they have a copy of what has been discussed over the phone.

    As these shipments need to ensure drug integrity during transit to the patient’s home, product temperature conditions must be strictly preserved; when necessary, appropriate packaging supplies such as temperature monitoring should be included.

    Once the patient receives the necessary materials and drug, a nurse can follow up with a home visit to administer the medication and perform health-related support as needed. If the drug can be self-administered, these visits may not be required.

    The study doctor will then follow up on the patient’s progress by telephone or alternative telemedicine methods. At this time, the doctor can respond to questions and share any study result updates.

    While these are key efforts to keep patients at home to reduce exposure to COVID-19, this is only a first step and does not meet the needs of every patient. Other advances in technology and digital documentation include remote monitoring and wearables that leverage newer innovations to improve patient safety, speed of information, and data accuracy. As an industry, we should take advantage of these more permanent technology-enabled solutions, for the greater benefit of patients and researchers alike.

    COVID-19, direct-to-patient, patient privacy
    Avatar

    Andrea Ochoa

    More posts by Andrea Ochoa

    Related Post

    • COVID-19 Update: What Sponsors Need to Know About the New FDA Guidance

      By Nach Davé | Comments are Closed

      With the emergence of the COVID-19 pandemic, we are all experiencing uncertainty. This uncertainty is impacting our personal lives, and it’s also impacting and reshaping the critical research biotech and specialty pharma companies are conducting.Read more

    • Statistical Considerations for FDA COVID-19 Guidance

      By Shari Medendorp | Comments are Closed

      In response to the newly released U.S. Food and Drug Administration (FDA) guidance on COVID-19, the Statistics Department at Premier Research has committed to highlight specific and necessary actionable considerations that directly address key FDARead more

    NextPrevious

    Recent Posts

    • Beware of Underestimating the Value of a Pre-NDA Meeting
    • Outsourcing-Pharma.com: Holistic Approach Benefits Drug Development
    • 5 Tips to Avoid an IND Clinical Hold: Regulatory Guidance and Insights
    • The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One
    • Creating a Compliant eCTD: Avoiding Common Regulatory and Technical Pitfalls on the Path to Submission

    Categories

    • Blog
    • CMC
    • COVID-19
    • FDA
    • INTERACT Meeting
    • News
    • Podcast
    • Regulatory Affairs
    • White Papers
    January 2021
    M T W T F S S
    « Nov    
     123
    45678910
    11121314151617
    18192021222324
    25262728293031

    Headquarters

    8000 Jarvis Ave.
    Suite 100
    Newark, CA 94560

    North Carolina

    One Park Drive, Suite 150
    Box 13608
    Research Triangle Park,
    NC 27709

    San Diego

    Aventine Building
    8910 University Center Lane
    Suite 400 San Diego, CA 92122

    United Kingdom

    250 South Oak Way
    Green Park
    Reading, Berkshire, RG2 6UG

    Australia

    Premier Research Australia Pty Ltd.
    Ground Floor, 23 Milton Parade
    Malvern VIC 3144

    • Home
    • About Us
    • Services
    • Cookie Policy
    • Privacy Notice
    • Contact
    Copyright 2020 Regulatory Professionals | All Rights Reserved
    • About Us
      • Our Story
      • Leadership
      • Senior Consultants
    • Services
      • Overview
      • Regulatory Affairs Strategy
      • Electronic Publishing | eCTD
      • Medical and Regulatory Writing
      • Quality Assurance
      • Project Management
      • Electronic Trial Master File | eTMF
    • Resources
      • Blog
      • White Papers
      • News
    • Careers
    • Contact
    Regulatory Professionals
    XWe use cookies (and equivalent technologies) to collect and analyze information on our Website’s performance and to enable the Website to function. Cookies also allow us and third parties to tailor the ads you see when you visit our Website and other third party websites in the same online network, including social networks. By clicking ‘AGREE', you agree to these uses of cookies. If you do not agree or if you would like more information, you can manage your cookie preferences by clicking on 'Cookie Settings'. Cookie Policy REJECTAGREECookie Settings
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non Necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

    Save & Accept